Cisplatin or Cetuximab and conventional versus redistributed radiation for advanced head and neck cancer
Phase 2
Withdrawn
- Conditions
- head and neck cancerOropharyngeal cancer1003866610046304
- Registration Number
- NL-OMON36211
- Lead Sponsor
- ederlands Kanker Instituut
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Withdrawn
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Stage III-IV T3-4 SCC Head and Neck, Oropharynx, Oral Cavity or Hypopharynx, Eligible for chemoradiation
Exclusion Criteria
Inability to receive one of the treatment arms, laryngeal cancer, previous malignancies
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>1. Primary Endpoints<br /><br>a. Locoregional recurrence free survival at two years<br /><br>b. Correlation of anatomical distribution of Zr89 Cetuximab uptake with<br /><br>treatment arm and anatomical location of recurrence</p><br>
- Secondary Outcome Measures
Name Time Method <p>2. Secondary Endpoints<br /><br>a. Quality of life during and after treatment, at 6 months and one year<br /><br>b. Swallowing function preservation at one year<br /><br>c. Progression Free Survival<br /><br>d. Overall Survival<br /><br>e. Toxicity</p><br>